These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 25466700)
1. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. Taylor-Cousar JL; Wiley C; Felton LA; St Clair C; Jones M; Curran-Everett D; Poch K; Nichols DP; Solomon GM; Saavedra MT; Accurso FJ; Nick JA J Cyst Fibros; 2015 Mar; 14(2):228-36. PubMed ID: 25466700 [TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446 [TBL] [Abstract][Full Text] [Related]
3. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding. Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108 [TBL] [Abstract][Full Text] [Related]
4. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral sildenafil in cystic fibrosis children with mild to moderate lung disease. Reisi M; Modaresi MR; Aghaii Z; Mirlohi SH; Rafiemanesh H; Azizi G; Sayedi SJ Pediatr Pulmonol; 2020 Jan; 55(1):156-160. PubMed ID: 31571429 [TBL] [Abstract][Full Text] [Related]
6. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis. Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Mindikoglu AL; Dowling TC; Schaub DJ; Hutson WR; Potosky DR; Christenson RH; Barth RN; LaMattina JC; Hanish SI; Weir MR; Raufman JP Dig Dis Sci; 2015 Nov; 60(11):3491-4. PubMed ID: 26143343 [TBL] [Abstract][Full Text] [Related]
8. Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum. Kummarapurugu AB; Zheng S; Pulsipher A; Savage JR; Ma J; Rubin BK; Kennedy TP; Voynow JA Am J Respir Cell Mol Biol; 2021 Feb; 64(2):260-267. PubMed ID: 33264072 [TBL] [Abstract][Full Text] [Related]
9. Sildenafil improves vascular endothelial function in patients with cystic fibrosis. Rodriguez-Miguelez P; Lee N; Tucker MA; Csányi G; McKie KT; Forseen C; Harris RA Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1486-H1494. PubMed ID: 30168731 [TBL] [Abstract][Full Text] [Related]
10. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum. Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923 [TBL] [Abstract][Full Text] [Related]
11. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. Barth P; Bruijnzeel P; Wach A; Sellier Kessler O; Hooftman L; Zimmermann J; Naue N; Huber B; Heimbeck I; Kappeler D; Timmer W; Chevalier E J Cyst Fibros; 2020 Mar; 19(2):299-304. PubMed ID: 31501052 [TBL] [Abstract][Full Text] [Related]
12. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Laguna TA; Wagner BD; Luckey HK; Mann SA; Sagel SD; Regelmann W; Accurso FJ Chest; 2009 Dec; 136(6):1561-1568. PubMed ID: 19567495 [TBL] [Abstract][Full Text] [Related]
13. Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity. Hair PS; Sass LA; Vazifedan T; Shah TA; Krishna NK; Cunnion KM PLoS One; 2017; 12(3):e0173257. PubMed ID: 28278205 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS; Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352 [TBL] [Abstract][Full Text] [Related]
15. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Sagel SD; Wagner BD; Anthony MM; Emmett P; Zemanick ET Am J Respir Crit Care Med; 2012 Nov; 186(9):857-65. PubMed ID: 22904182 [TBL] [Abstract][Full Text] [Related]
16. On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients. Morla S; Sankaranarayanan NV; Afosah DK; Kumar M; Kummarapurugu AB; Voynow JA; Desai UR J Med Chem; 2019 Jun; 62(11):5501-5511. PubMed ID: 31074986 [TBL] [Abstract][Full Text] [Related]
17. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Mayer-Hamblett N; Aitken ML; Accurso FJ; Kronmal RA; Konstan MW; Burns JL; Sagel SD; Ramsey BW Am J Respir Crit Care Med; 2007 Apr; 175(8):822-8. PubMed ID: 17234902 [TBL] [Abstract][Full Text] [Related]
18. A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio Ring A; Morris T; Wozniak M; Sullo N; Dott W; Verheyden V; Kumar T; Brunskill N; Vaja R; Murphy GJ Br J Clin Pharmacol; 2017 Apr; 83(4):709-720. PubMed ID: 27779776 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768 [TBL] [Abstract][Full Text] [Related]
20. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Konstan MW; Döring G; Heltshe SL; Lands LC; Hilliard KA; Koker P; Bhattacharya S; Staab A; Hamilton A; J Cyst Fibros; 2014 Mar; 13(2):148-55. PubMed ID: 24440167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]